First Patient Dosed with SIM0500 in US Trial for Multiple Myeloma Combat Simcere Zaiming has initiated a Phase 1 trial of SIM0500 for treating relapsed/refractory multiple myeloma in the US, marking a crucial step in oncology.

First Patient Dosed with SIM0500 in US Trial for Multiple Myeloma Combat #USA #New_York #Simcere #Zaiming #SIM0500